Related Experiment Videos
Hepatocellular carcinoma: current management and future trends
1Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh Medical Center, BST, E 1552, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA. carrbi@upmc.edu
Gastroenterology
|October 28, 2004
Summary
Hepatocellular carcinoma (HCC) is often diagnosed late, with limited treatment options and high recurrence rates. New, well-tolerated therapies are urgently needed to improve survival for patients with this advanced liver cancer.
Area of Science:
- Hepatology
- Medical Oncology
- Surgical Oncology
Background:
- Hepatocellular carcinoma (HCC) frequently presents at advanced stages, often co-occurring with cirrhosis.
- Surgical resection, the preferred treatment, is feasible for few patients due to late diagnosis and high recurrence rates.
- Current adjuvant therapies like chemoembolization and neoadjuvant treatments have not demonstrated significant benefits in preventing HCC recurrence.
Purpose of the Study:
- To review the current treatment landscape for hepatocellular carcinoma (HCC).
- To identify limitations of existing therapies and unmet needs in HCC management.
- To highlight promising novel therapeutic agents for HCC.
Main Methods:
- Literature review of current and emerging treatments for HCC.
- Analysis of the efficacy and tolerability of surgical resection, liver transplantation, chemoembolization, and chemotherapy.
- Evaluation of novel therapeutic strategies, including targeted therapies and radiopharmaceuticals.
Main Results:
- Surgical resection and liver transplantation offer curative potential but are limited to a small patient subset.
- Chemoembolization may prolong survival in selected unresectable HCC patients.
- Standard chemotherapy (doxorubicin, cisplatin) shows low response rates and poor tolerability in patients with cirrhosis.
Conclusions:
- There is a critical need for prospective trials to establish optimal management strategies for HCC.
- Development of novel, non-cytotoxic, and well-tolerated therapeutic agents is essential for patients with underlying cirrhosis.
- Emerging treatments such as 90Y microspheres, antiangiogenesis agents, growth factor inhibitors, and K vitamins show promise for improving HCC outcomes.